Sub-stratification of type-2 high airway disease for therapeutic decision-making: a ‘bomb' (blood eosinophils) meets ‘magnet' (FeNO) framework

Sub-stratification of type-2 high airway disease for therapeutic decision-making: a ‘bomb' (blood eosinophils) meets ‘magnet' (FeNO) framework

Dades bibliogràfiques
Autors principals:	Couillard, S, Pavord, I, Heaney, L, Petousi, N, Hinks, T
Format:	Journal article
Idioma:	English
Publicat:	Wiley 2022

Ítems similars

FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
per: Couillard, S, et al.
Publicat: (2021)

FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
per: Couillard, S, et al.
Publicat: (2021)

Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing
per: Couillard, S, et al.
Publicat: (2022)

Mechanisms of FeNO non-suppression in severe asthma: analysis of sputum type 2 cytokines and chemokines
per: Couillard, S, et al.
Publicat: (2020)

Feno and blood eosinophils as biomarkers in predicting asthma exacerbations
per: Rastogi, S, et al.
Publicat: (2017)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
per: Moran, AM, et al.
Publicat: (2020)

Eosinophilic phenotypes of airway disease.
per: Pavord, I
Publicat: (2013)

Prognostic value of using FeNO to guide step-down treatment decisions in asthma
per: Wang, K, et al.
Publicat: (2018)

Eosinophils in asthma and airway hyperresponsiveness.
per: Brightling, C, et al.
Publicat: (2004)

FeNO-based asthma management results in faster improvement of airway hyperresponsiveness
per: Katrine Feldballe Bernholm, et al.
Publicat: (2018-10-01)

Does a composite score combining peripheral blood eosinophils (PBE) and exhaled nitric oxide (FeNO) accurately predict a sputum eosinophilia?
per: Connolly, CM, et al.
Publicat: (2017)

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
per: Couillard, S, et al.
Publicat: (2021)

Exhaled Nitric Oxide (FeNO) as a Non-Invasive Marker of Airway Inflammation
per: Mitsuru Munakata
Publicat: (2012-01-01)

The Pitfalls of FeNO Testing
per: Sujoy Khan
Publicat: (2013-01-01)

The Lancet COPD Commission: broader questions remain
per: Petousi, N, et al.
Publicat: (2023)

The significance of eosinophilic airway inflammation in asthma
per: Pavord, I, et al.
Publicat: (2002)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
per: Moran, A, et al.
Publicat: (2020)

Toward a predict and prevent approach in obstructive airway diseases
per: Couillard, S, et al.
Publicat: (2023)

Comparison of airway immunopathology of eosinophilic bronchitis and asthma.
per: Brightling, C, et al.
Publicat: (2003)

The making of the atomic bomb /
per: 435392 Rhodes, Richard
Publicat: (1986)

Prognostic value of FeNO-guided assessment to identify steroid-responsive respiratory symptoms
per: Wang, K, et al.
Publicat: (2018)

Association Between FeNO, Total Blood IgE, Peripheral Blood Eosinophil and Inflammatory Cytokines in Partly Controlled Asthma
per: Badar A, et al.
Publicat: (2020-10-01)

Current evidence and future research needs for FeNO measurement in respiratory diseases
per: Bjermer, L, et al.
Publicat: (2014)

Current evidence and future research needs for FeNO measurement in respiratory diseases.
per: Bjermer, L, et al.
Publicat: (2014)

Update on the Role of FeNO in Asthma Management
per: Neveda Murugesan, et al.
Publicat: (2023-04-01)

Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis.
per: Brightling, C, et al.
Publicat: (2000)

Association of general and abdominal obesity with lung function, FeNO, and blood eosinophils in adult asthmatics: Findings from NHANES 2007–2012
per: Haoyu Zhang, et al.
Publicat: (2023-02-01)

Eosinophils in Asthma and Airway Hyperresponsiveness [3] (multiple letters)
per: Brightling, C, et al.
Publicat: (2004)

What is the added value of FeNO as T2 biomarker?
per: María Celeste Marcos, et al.
Publicat: (2022-08-01)

Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma.
per: Kulkarni, N, et al.
Publicat: (2010)

Exposure to organophosphate flame retardants and plasticizers is positively associated with wheeze and FeNO and eosinophil levels among school-aged children: The Hokkaido study
per: Yi Zeng, et al.
Publicat: (2023-11-01)

Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment
per: Lavoie, G, et al.
Publicat: (2024)

Measuring lung function in airways diseases: current and emerging techniques
per: Petousi, N, et al.
Publicat: (2019)

Dark sun : the making of the hydrogen bomb /
per: 435392 Rhodes, Richard
Publicat: (1995)

Type-2 inflammation: a key treatable trait associated with lung function decline in chronic airways disease
per: Petousi, N, et al.
Publicat: (2024)

IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma
per: Jorge Sánchez, et al.
Publicat: (2021-03-01)

The change of FeNO is correlated with asthma control and lung function
per: Yanmin Gao, et al.
Publicat: (2024-10-01)

FeNO as a biomarker for airway inflammation due to exposure to air pollutants among school children nearby industrial areas in Terengganu
per: Kamaruddin, Anis Syafiqah, et al.
Publicat: (2019)

Blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO) for steroid stewardship in chronic obstructive pulmonary disorder (COPD): A systematic review
per: Aditi Dhawan, et al.
Publicat: (2024-09-01)

Nasal Airflow Measured by Rhinomanometry Correlates with FeNO in Children with Asthma.
per: I-Chen Chen, et al.
Publicat: (2016-01-01)